# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Sean Lee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $2 price tar...
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of ...
Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments...
Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments...
JonesTrading analyst Soumit Roy upgrades Monopar Therapeutics (NASDAQ:MNPR) from Hold to Buy and announces $2 price target.